Bristol Myers Squibb can grow through Revlimid generics, execs insist, pointing to key launches

When Bristol Myers Squibb picked up Celgene in its massive 2019 buyout, a key question lingering over the deal was the timing around Revlimid generics. They're now a little more than a year away thanks to a patent settlement, and Bristol execs are busy detailing how the company will continue to grow through the megablockbuster’s decline.

In short, the answer is new drug launches. BMS is in the early stages of rollouts for anemia med Reblozyl, multiple sclerosis drug Zeposia and acute myeloid leukemia therapy Onureg. The drugs generated $138 million in the fourth quarter of 2020 and $303 million during the year. Still, that's far short of the megabillions generated by blood cancer med Revlimid.